Literature DB >> 27853993

The roles of ebolavirus glycoproteins in viral pathogenesis.

Yun-Jia Ning1, Fei Deng1, Zhihong Hu1, Hualin Wang2.   

Abstract

Ebolaviruses are highly dangerous pathogens exhibiting extreme virulence in humans and nonhuman primates. The majority of ebolavirus species, most notably Zaire ebolavirus, can cause Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, in humans. EVD is associated with case-fatality rates as high as 90%, and there is currently no specific treatment or licensed vaccine available against EVD. Understanding the molecular biology and pathogenesis of ebolaviruses is important for the development of antiviral therapeutics. Ebolavirus encodes several forms of glycoproteins (GPs), which have some interesting characteristics, including the transcriptional editing coding strategy and extensive O-glycosylation modification, clustered in the mucin-like domain of GP1, full-length GP (GP1,2), and shed GP. In addition to the canonical role of the spike protein, GP1,2, in viral entry, ebolavirus GPs appear to have multiple additional functions, likely contributing to the complex pathogenesis of the virus. Here, we review the roles of ebolavirus GPs in viral pathogenesis.

Entities:  

Keywords:  cytotoxicity; ebolavirus; glycoprotein (GP); immune evasion; inflammation; mucin-like domain (MLD); pathogenesis

Mesh:

Substances:

Year:  2016        PMID: 27853993      PMCID: PMC6791933          DOI: 10.1007/s12250-016-3850-1

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  120 in total

1.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Authors:  John Misasi; Morgan S A Gilman; Masaru Kanekiyo; Miao Gui; Alberto Cagigi; Sabue Mulangu; Davide Corti; Julie E Ledgerwood; Antonio Lanzavecchia; James Cunningham; Jean Jacques Muyembe-Tamfun; Ulrich Baxa; Barney S Graham; Ye Xiang; Nancy J Sullivan; Jason S McLellan
Journal:  Science       Date:  2016-02-25       Impact factor: 47.728

2.  Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Authors:  Jean K Gustin; Ying Bai; Ashlee V Moses; Janet L Douglas
Journal:  J Infect Dis       Date:  2015-03-27       Impact factor: 5.226

Review 3.  Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Authors:  Ilhem Messaoudi; Gaya K Amarasinghe; Christopher F Basler
Journal:  Nat Rev Microbiol       Date:  2015-10-06       Impact factor: 60.633

4.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

Authors:  Nanette Van Damme; Daniel Goff; Chris Katsura; Rebecca L Jorgenson; Richard Mitchell; Marc C Johnson; Edward B Stephens; John Guatelli
Journal:  Cell Host Microbe       Date:  2008-03-13       Impact factor: 21.023

5.  Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane.

Authors:  Jason Hammonds; Jaang-Jiun Wang; Hong Yi; Paul Spearman
Journal:  PLoS Pathog       Date:  2010-02-05       Impact factor: 6.823

Review 6.  Immune evasion strategies of flaviviruses.

Authors:  Jing Ye; Bibo Zhu; Zhen F Fu; Huanchun Chen; Shengbo Cao
Journal:  Vaccine       Date:  2012-11-13       Impact factor: 3.641

7.  Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.

Authors:  Sabine Kupzig; Viktor Korolchuk; Ruth Rollason; Anna Sugden; Andrew Wilde; George Banting
Journal:  Traffic       Date:  2003-10       Impact factor: 6.215

Review 8.  Interferon-inducible antiviral effectors.

Authors:  Anthony J Sadler; Bryan R G Williams
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

9.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

10.  The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial for Inflammatory Response Induced by Ebola Virus Glycoprotein.

Authors:  Dianyuan Zhao; Xintao Han; Xuexing Zheng; Hualei Wang; Zaopeng Yang; Di Liu; Ke Han; Jing Liu; Xiaowen Wang; Wenting Yang; Qingyang Dong; Songtao Yang; Xianzhu Xia; Li Tang; Fuchu He
Journal:  PLoS Pathog       Date:  2016-03-04       Impact factor: 6.823

View more
  8 in total

1.  Ebola virus VP35 has novel NTPase and helicase-like activities.

Authors:  Ting Shu; Tianyu Gan; Peng Bai; Xiaotong Wang; Qi Qian; Hui Zhou; Qi Cheng; Yang Qiu; Lei Yin; Jin Zhong; Xi Zhou
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

2.  Increased Pathogenicity and Virulence of Middle East Respiratory Syndrome Coronavirus Clade B In Vitro and In Vivo.

Authors:  Yanqun Wang; Jing Sun; Xiaobo Li; Airu Zhu; Wenda Guan; De-Qiang Sun; Jingxian Zhao; Jicheng Huang; Jincun Zhao; Mian Gan; Xuefeng Niu; Jun Dai; Lu Zhang; Zhaoyong Zhang; Yongxia Shi; Shuxiang Huang; Chris Ka Pun Mok; Zifeng Yang; Zhongfang Wang; Wenjie Tan; Yimin Li; Ling Chen; Rongchang Chen; Malik Peiris; Nanshan Zhong
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

3.  Ebola virus mucin-like glycoprotein (Emuc) induces remarkable acute inflammation and tissue injury: evidence for Emuc pathogenicity in vivo.

Authors:  Yun-Jia Ning; Zhenyu Kang; Jingjun Xing; Yuan-Qin Min; Dan Liu; Kuan Feng; Manli Wang; Fei Deng; Yiwu Zhou; Zhihong Hu; Hualin Wang
Journal:  Protein Cell       Date:  2018-04       Impact factor: 14.870

Review 4.  Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach.

Authors:  Titus Abiola Olukitibi; Zhujun Ao; Mona Mahmoudi; Gary A Kobinger; Xiaojian Yao
Journal:  Microorganisms       Date:  2019-09-29

Review 5.  Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production.

Authors:  Kostlend Mara; Meiling Dai; Aaron M Brice; Marina R Alexander; Leon Tribolet; Daniel S Layton; Andrew G D Bean
Journal:  Vaccines (Basel)       Date:  2021-01-17

6.  A Critical Domain of Ebolavirus Envelope Glycoprotein Determines Glycoform and Infectivity.

Authors:  Haruhiko Fujihira; Katsuaki Usami; Keita Matsuno; Hideyuki Takeuchi; Kaori Denda-Nagai; Jun-Ichi Furukawa; Yasuro Shinohara; Ayato Takada; Yoshihiro Kawaoka; Tatsuro Irimura
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

7.  Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus.

Authors:  Haley L DeMers; Shihua He; Sujata G Pandit; Emily E Hannah; Zirui Zhang; Feihu Yan; Heather R Green; Denise F Reyes; Derrick Hau; Megan E McLarty; Louis Altamura; Cheryl Taylor-Howell; Marcellene A Gates-Hollingsworth; Xiangguo Qiu; David P AuCoin
Journal:  PLoS Negl Trop Dis       Date:  2020-11-03

8.  Ebola Virus GP Activates Endothelial Cells via Host Cytoskeletal Signaling Factors.

Authors:  Benedicte Mpia Moni; Yasuteru Sakurai; Jiro Yasuda
Journal:  Viruses       Date:  2022-01-13       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.